发明名称 CANNABINOID RECEPTOR LIGAND
摘要 <P>PROBLEM TO BE SOLVED: To provide a compound which can be useful as a cannabinoid receptor ligand. Ž<P>SOLUTION: A compound of formula (I), or a pharmaceutically acceptable salt of the compound exhibits anti-inflammatory and immunomodulatory activity. A pharmaceutical composition contains the compound. The compound can be useful in the treatment of various medical conditions including cutaneous T-cell lymphoma, rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, glaucoma, diabetes, sepsis, shock, sarcoidosis, idiopathic pulmonary fibrosis, bronchopulmonary dysplasia, retinal disease, scleroderma, osteoporosis, renal ischemia, myocardial infarction, cerebral stroke, cerebral ischemia, nephritis, hepatitis, glomerulonephritis, cryptogenic fibrosing aveolitis, psoriasis, transplant rejection, atopic dermatitis, vasculitis, allergy, seasonal allergic rhinitis, Crohn's disease, inflammatory bowel disease, reversible airway obstruction, adult respiratory distress syndrome, asthma, chronic obstructive pulmonary disease (COPD) or bronchitis. Ž<P>COPYRIGHT: (C)2010,JPO&INPIT Ž
申请公布号 JP2010018635(A) 申请公布日期 2010.01.28
申请号 JP20090245983 申请日期 2009.10.26
申请人 SCHERING CORP 发明人 FRIARY RICHARD J;KOZLOWSKI JOSEPH A;SHANKAR BANDARPALLE B;WONG MICHAEL K C;ZHOU GUOWEL;LAVEY BRIAN J;SHIH NENG-YANG;TONG LING;CHEN LEI;SHU YOUHENG
分类号 C07D211/96;A61K31/445;A61K31/4535;A61K31/454;A61K45/00;A61P1/04;A61P1/16;A61P3/10;A61P9/10;A61P11/00;A61P11/06;A61P13/12;A61P17/00;A61P17/02;A61P17/06;A61P19/02;A61P19/10;A61P25/00;A61P27/02;A61P27/06;A61P27/16;A61P29/00;A61P35/00;A61P37/02;A61P37/06;A61P37/08;C07D211/26;C07D401/06;C07D401/12;C07D403/12;C07D405/12;C07D409/12;C07D413/12 主分类号 C07D211/96
代理机构 代理人
主权项
地址